GH Research plc (NASDAQ: GHRS) is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.

Acuta Capital Partners

Cormorant Asset Management

RA Capital Management

RTW Investments

Logos Capital

Biotechnology Value Fund

Boxer Capital

BVF Partners

Surveyor Capital

Venrock Healthcare Capital Partners

Verition Fund Management

GH Research plc

GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights

GH Research Provides Business Updates and Highlights Key Upcoming Milestones

https://lnkd.in/eEJUSZpQ

COMPASS Pathways is a biotech company focused on developing mental health therapies, including psilocybin-based treatments.

COMPASS Pathways

Cybin is a biotechnology company specializing in psychedelic drug development for various mental health conditions.

Cybin

Entheon is a biopharmaceutical company dedicated to developing psychedelic medicines for the treatment of addiction and other mental health disorders.

Entheon

GH Research is a clinical-stage biopharmaceutical company focused on developing therapies for psychiatric and neurological disorders. Their lead program, GH001, is an inhalable mebufotenin product candidate being investigated for treatment-resistant depression.

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

GH Research PLC

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 4, 2024 6:37 PM	c89f880a
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 4, 2024 6:37 PM	e71ec37d
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Mar 4, 2024 6:37 PM	d1cf9bed
translate crunchbase fundingrounds	general
peers	general
news basic	general	Mar 4, 2024 6:37 PM	d67d16ff
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:GHRES

GH Research PLC

Last Close

9.62

22/11 21:00

Market Cap

591.56M

Beta: -

Volume Today

61.64K

Avg: -